HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.3%

Neg 0% Neu 89.3% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.